|
2025
|
Invention
|
Use of a ppar-delta agonist for reducing loss of muscle strength, muscle mass, or type i muscle f... |
|
2024
|
Invention
|
Solid compositions comprising a glucokinase activator and methods of making and using the same.
... |
|
|
Invention
|
Therapeutic uses of glp1r agonists.
Methods of using glucagon-like peptide 1 receptor (GLP1R) ag... |
|
|
Invention
|
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs.
Metho... |
|
2023
|
Invention
|
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof.... |
|
2022
|
Invention
|
Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl)-phenoxy)-propyl]-... |
|
|
Invention
|
Solid composition of glp-1 receptor agonist.
Provided in the present invention is a pharmaceutic... |
|
|
Invention
|
Solid composition of glp-1 receptor agonist. Provided in the present invention is a pharmaceutica... |
|
2021
|
Invention
|
Amorphous form of isoquinoline derivative.
The present invention provides an amorphous form of (... |
|
|
Invention
|
Amorphous form of isoquinoline derivative. The present invention provides an amorphous form of (S... |
|
|
Invention
|
Crystalline form of hydrochloride salt of quinoline derivative.
The present disclosure relates t... |
|
|
Invention
|
Crystalline form of hydrochloride salt of quinoline derivative. The present disclosure relates to... |
|
|
Invention
|
Substituted fused imidazole derivatives and methods of treating sickle cell disease and related c... |
|
|
P/S
|
Pharmaceutical preparations for human use, namely anti-diabetic drugs |
|
|
Invention
|
Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl... |
|
|
Invention
|
Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfa... |
|
|
Invention
|
Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfany... |
|
|
Invention
|
Methods of inhibiting osteoclastogenesis and osteoclast activity.
The present invention provides... |
|
|
Invention
|
Intermediates and methods for preparing a glp-1 receptor agonist. The present invention relates t... |
|
|
Invention
|
Methods for preparing methyl (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionate and hyd... |
|
|
Invention
|
Methods of treating cognitive impairment or improving cognitive function.
The present invention ... |
|
|
Invention
|
Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4 yl}-phenoxy)-propyl]-... |
|
|
Invention
|
Phenoxy acetic acids and phenyl propionic acids as ppar delta agonists. Phenoxy acetic acids and ... |
|
|
Invention
|
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs. Method... |
|
|
Invention
|
Sulfoxide and sulfone glucokinase activators and methods of use thereof. This application relates... |
|
|
Invention
|
Substituted fused imidazole derivatives and methods of treating refractive ocular disorders.
The... |
|
|
Invention
|
Substituted fused imidazole derivatives and methods of treating refractive ocular disorders. The ... |
|
2020
|
Invention
|
Bach1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof.
Th... |
|
|
Invention
|
Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-... |
|
|
Invention
|
Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-... |
|
|
Invention
|
Quinoline derivatives, pharmaceutically acceptable salts, and methods of use thereof.
The presen... |
|
|
Invention
|
Quinoline derivatives, pharmaceutically acceptable salts, and methods of use thereof. transtrans-... |
|
|
Invention
|
Glucokinase activator compositions for the treatment of diabetes. The present invention relates t... |
|
2019
|
Invention
|
Methods of inhibiting osteoclastogenesis and osteoclast activity. The present invention provides ... |
|
|
Invention
|
Use of a ppar-δ agonist for reducing loss of muscle strength, muscle mass, or type i muscle fiber... |
|
|
Invention
|
Glucokinase activator compositions for the treatment of cognitive impairment. The present inventi... |
|
|
Invention
|
Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop... |
|
|
Invention
|
Bach1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof. The... |
|
2018
|
P/S
|
Pharmaceutical preparations for the treatment of Alzheimer's disease, dementia, central nervous s... |
|
2017
|
P/S
|
Providing medical laboratory services; providing medical laboratory services, namely, bioanalytic... |
|
2015
|
P/S
|
Pharmaceutical preparations for human use, namely, pharmaceutical preparations for the treatment ... |
|
|
P/S
|
Pharmaceutical preparations for human use; pharmaceutical preparations for human use, namely, pha... |
|
|
P/S
|
Pharmaceutical drug development services and consultation services related thereto; pharmaceutica... |
